YGION Biomedical announces €15 Million Series A Financing to develop Individualized Cancer Immunotherapies

YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, has announced the completion of a Series A financing round of €15 million from an Austrian private trust. The proceeds will be used to further develop YGION’s unique YGNITE™ technology platform and advance the lead program YG-01 into preclinical and clinical development.